Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.

التفاصيل البيبلوغرافية
العنوان:	Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.
المؤلفون:	Alkadimi MA; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Aldawoodi TA; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Lucero KT; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Fierro ME; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Boyle LD; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Mader MJ; South Texas Veterans Health Care System, San Antonio, TX, USA., Franklin KR; South Texas Veterans Health Care System, San Antonio, TX, USA., Arora SP; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Nooruddin Z; Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.; South Texas Veterans Health Care System, San Antonio, TX, USA.
المصدر:	The oncologist [Oncologist] 2024 May 03; Vol. 29 (5), pp. 369-376.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2022- : Oxford : Oxford University Press Original Publication: Dayton, Ohio : AlphaMed Press, c1996-
مواضيع طبية MeSH:	Liver Neoplasms/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/mortality , Liver Neoplasms/therapy , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/therapy, Humans ; Male ; Female ; Aged ; Retrospective Studies ; Middle Aged ; United States/epidemiology ; Antibodies, Monoclonal, Humanized/therapeutic use ; United States Department of Veterans Affairs/statistics & numerical data ; Bevacizumab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome ; Veterans Health/statistics & numerical data
مستخلص:	Purpose: This study retrospectively reviewed the outcomes of patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab with bevacizumab (A + B) therapy at the Veterans Health Administration (VHA). Patients and Methods: Patients with advanced HCC who received first-line systemic therapy with A + B at the VHA between December 1, 2019, and March 1, 2022, were selected from electronic medical records (EMR) using ICD-9 and ICD-10 codes. Abstractors reviewed the EMR of the patients from their index date of A + B initiation until death or their last VHA visit, with the study period ending on January 31, 2023. The chi-square test was used to compare rates, and the Mann-Whitney test was used to compare medians. Results: A total of 332 patients met the study criteria. The median age was 67 years; 99% were male, 63% were non-Hispanic Whites, 26% were Black, and 66% had an Eastern Cooperative Oncology Group performance status of ≥1. 84% had child Pugh score (CPS) class A, 16% had CPS classes B and C, 62% had a grade 2 albumin-bilirubin score, 56% had HCC caused by viral hepatitis, 80% had cirrhosis, and 67% had received prior local therapies. The 6-month progression-free survival (PFS) was 59%, while the 1-year PFS rate was 36%. Overall survival (OS) at 1-year was 52% in our study. Conclusion: In real world, despite having similar PFS as the phase III IMbrave 150 trial, our OS at 12 months was lower (52% vs. 67%) because our study included a higher proportion of elderly patients with moderate liver dysfunction and a 40% non-White. This study provided real-world outcomes that differed from the study population in a pivotal trial. (Published by Oxford University Press 2024.)
References:	N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514) Lancet Oncol. 2019 Feb;20(2):282-296. (PMID: 30665869) J Hepatol. 2022 Apr;76(4):862-873. (PMID: 34902530) Dig Dis Sci. 2018 May;63(5):1173-1181. (PMID: 29508165) J Clin Exp Hepatol. 2023 Jul-Aug;13(4):618-623. (PMID: 37440938) Eur J Cancer. 2022 Feb;162:76-98. (PMID: 34954439) NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. (PMID: 38319892) Lancet. 2018 Mar 24;391(10126):1163-1173. (PMID: 29433850) Nature. 2021 Apr;592(7854):450-456. (PMID: 33762733) Lancet. 2017 Jan 7;389(10064):56-66. (PMID: 27932229) Hepatol Res. 2022 Jan;52(1):67-74. (PMID: 34520619) Aliment Pharmacol Ther. 2023 Jun;57(11):1313-1325. (PMID: 36883351) J Clin Oncol. 2020 Dec 20;38(36):4317-4345. (PMID: 33197225) Liver Cancer. 2022 Jul 13;11(6):558-571. (PMID: 36589722) Lancet Oncol. 2022 Jan;23(1):77-90. (PMID: 34914889) J Clin Oncol. 2020 Jan 20;38(3):193-202. (PMID: 31790344) N Engl J Med. 2018 Jul 05;379(1):54-63. (PMID: 29972759) N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160) JAMA Oncol. 2020 Nov 01;6(11):e204564. (PMID: 33001135) JHEP Rep. 2021 Aug 05;3(5):100347. (PMID: 34505035) Hepatology. 2022 Oct;76(4):1000-1012. (PMID: 35313048) Cancers (Basel). 2021 Aug 05;13(16):. (PMID: 34439111) J Clin Oncol. 2021 Jul 1;39(19):2115-2127. (PMID: 34043444) Cancers (Basel). 2021 Jun 03;13(11):. (PMID: 34205099) J Geriatr Oncol. 2020 May;11(4):557-565. (PMID: 31704038)
فهرسة مساهمة:	Keywords: atezolizumab; bevacizumab; hepatocellular carcinoma; real-world evidence
المشرفين على المادة:	0 (Antibodies, Monoclonal, Humanized) 2S9ZZM9Q9V (Bevacizumab) 52CMI0WC3Y (atezolizumab)
تواريخ الأحداث:	Date Created: 20240123 Date Completed: 20240503 Latest Revision: 20240505
رمز التحديث:	20240505
مُعرف محوري في PubMed:	PMC11067802
DOI:	10.1093/oncolo/oyad343
PMID:	38254242
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	1549-490X
DOI:	10.1093/oncolo/oyad343